Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-intensity chemotherapy with or without imatinib in older unfit patients with previously untreated AML or advanced MDS
ISRCTN70542454Phase 2Completed
- Sponsor
- HOVON
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imatinib, cytarabine and daunorubicin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by HOVON. Primary endpoint: Complete remission rate. Started Jan 2006; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN70542454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN70542454.